Sciele Pharma, Inc. (NASDAQ:SCRX), a specialty pharmaceutical
company, will release financial results for the second quarter ended
June 30, 2008, after the market closes on Wednesday, July 30, 2008.
Conference Call
Sciele will also host a conference call on Wednesday, July 30, beginning
at 4:30 p.m. Eastern Time to discuss the financial results and provide a
business update. Analysts, investors and other interested parties are
invited to participate by visiting the Company's website, http://www.sciele.com,
and entering the Investor Relations page. You may also dial in to listen
to the conference call. The dial-in numbers are (888) 228-5279 for
domestic callers and (913) 312-1422 international callers. All callers
should use passcode 1732104 to gain access to the conference call.
Please plan to dial-in or log on at least ten minutes prior to the
designated start time so management can begin promptly.
Replay
A seven-day telephonic replay of this conference call will be available
by dialing (888) 203-1112 for domestic callers and (719) 457-0820 for
international callers. Callers should use the passcode 1732104 to gain
access to the replay, which will be available through the end of the day
on August 6, 2008. The webcast replay will be available on the Investor
Relations page of the Company's website for seven days.
Sciele Pharma, Inc. Background
Sciele Pharma, Inc. is a pharmaceutical company specializing in sales,
marketing and development of branded prescription products focused on
the therapeutic areas of Cardiovascular, Diabetes, Women's Health and
Pediatrics. The Company's Cardiovascular and Diabetes products treat
patients with high cholesterol, hypertension, high triglycerides,
unstable angina and Type 2 diabetes; its Women's Health products are
designed to improve the health and well-being of women and mothers and
their babies; and its Pediatrics products treat allergies, asthma,
coughs and colds, and attention deficit and hyperactivity disorder
(ADHD). Founded in 1992 and headquartered in Atlanta, Georgia, Sciele
employs more than 900 people. The Company's success is based on placing
the needs of patients first, improving health and quality of life, and
implementing its business platform – an
Entrepreneurial Spirit, Innovation, Execution Excellence, Simplicity,
and Teamwork.
Sciele Pharma, Inc.
Joseph T. Schepers, 678-341-1401
ir@sciele.com
